In a report published Tuesday, FBR Capital analysts initiated coverage on Juno Therapeutics Inc. (JUNO) with a ‘Outperform‘ rating and $73 price target.
Currently, there are 4 analysts that rate JUNO a ‘Buy’ vs. 3 rating it a ‘Hold’. No analyst rates it a ‘Sell’. The name has a median Wall Street price target of $67.00 with a high target of $78.00.
In the past 52 weeks, shares of Seattle, Washington-based biopharmaceutical company have traded between a low of $37.69 and a high of $69.28 and are now at $44.00.
Juno shares are up year-over-year ; down 20.41% year-to-date.
Analysts at Imperial Capital are out with a report this morning upgrading shares of FireEye, Inc. (FEYE) with a ‘Outperform‘ from ‘In-line‘ rating. The firm raised its price target for the company to $55 from $45.
FireEye Inc. shares have t-12 price-to-sales ratio of 13.14. EPS for the same period is ($3.30).
The stock of the Milpitas, California-based company is up 46.53% year-over-year and 38.22% year-to-date.
Incyte Corporation (INCY) was reiterated a ‘Buy’ by Argus analysts on Tuesday. The broker also raised its price target on the stock to $135 from $125 noting given its deep pipeline, the biopharmaceutical company could be a takeover candidate.
On valuation measures, Incyte Corp. shares are currently priced at 1,495.71x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of (9.46) and 168.16, respectively. Price/Sales for the same period is 32.10 while EPS is $0.08. Currently, there are 12 analysts that rate INCY a ‘Buy‘, 1 rates it a ‘Hold‘. No analyst rates it a ‘Sell‘.
INCY has a median Wall Street price target of $125.50 with a high target of $130.00.
Cigna Corp. (CI) was reiterated as ‘Sector Perform’ with $182 from $184 price target on Tuesday by RBC Capital Markets.
CI is currently printing a normal average trading volume with the issue trading 1.07 million shares, compared to the average volume of 2.71 million. The stock began trading this morning at $146.76 to currently trade 1.19% higher from the prior days close of $146.59. On an intraday basis it has gotten as low as $146.53 and as high as $149.26.
Cigna Corp. shares are priced at 18.37x this year’s forecasted earnings, compared to the industry’s 14.96x earnings multiple. The company’s current year and next year EPS growth estimates stand at 15.90% and 10.10% compared to the industry growth rates of 11.20% and 8.90%, respectively. CI has a t-12 price-to-sales ratio of 1.03. EPS for the same period registers at $8.07.
Cigna Corp. shares have declined 4.45% in the last 4 weeks while advancing 9.99% in the past three months. Over the past 5 trading sessions the stock has gained 0.62%.
The Bloomfield, Connecticut-based company, which is currently valued at $38.19 billion, has a median Wall Street price target of $175 with a high target of $190.
Cigna’s stock is up 58.42% year-over-year, compared with a 6.63% gain in the S&P 500.